Alexei F Kisselev

Summary

Affiliation: Dartmouth Medical School
Country: USA

Publications

  1. pmc Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib
    Tamer B Shabaneh
    Norris Cotton Cancer Center, The Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, United States of America
    PLoS ONE 8:e56132. 2013
  2. doi request reprint A novel bullet hits the proteasome
    Alexei F Kisselev
    Department of Pharmacology and Toxicology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, 1 Medical Center Drive, Lebanon, NH 03756, USA Electronic address
    Cancer Cell 24:691-3. 2013
  3. pmc Proteasome inhibitors: an expanding army attacking a unique target
    Alexei F Kisselev
    Department of Pharmacology and Toxicology, Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, NH 03756, USA
    Chem Biol 19:99-115. 2012
  4. doi request reprint Joining the army of proteasome inhibitors
    Alexei F Kisselev
    Norris Cotton Cancer Center and Department of Pharmacology and Toxicology, Dartmouth Medical School, Lebanon, NH 03756, USA
    Chem Biol 15:419-21. 2008
  5. pmc Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib
    Anne C Mirabella
    Department of Pharmacology and Toxicology, Dartmouth Medical School, Dartmouth College, Lebanon, NH 03756, USA
    Chem Biol 18:608-18. 2011
  6. pmc Nature of pharmacophore influences active site specificity of proteasome inhibitors
    Michael Screen
    Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, New Hampshire 03755, USA
    J Biol Chem 285:40125-34. 2010
  7. pmc Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites
    Matthew Britton
    Department of Pharmacology and Toxicology, Dartmouth Medical School, 1 Medical Center Drive, HB7936, Lebanon, NH 03756, USA
    Chem Biol 16:1278-89. 2009
  8. doi request reprint Cell-line-specific high background in the Proteasome-Glo assay of proteasome trypsin-like activity
    Owen M Wilkins
    Department of Pharmacology and Toxicology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA
    Anal Biochem 451:1-3. 2014
  9. pmc Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA
    Tina C Albershardt
    Department of Pharmacology and Toxicology, Dartmouth Medical School, Lebanon, New Hampshire 03756, USA
    J Biol Chem 286:24882-95. 2011
  10. ncbi request reprint Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates
    Alexei F Kisselev
    Department of Pharmacology and Toxicology, and Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, NH 03756, USA
    Methods Enzymol 398:364-78. 2005

Collaborators

  • Bogdan I Florea
  • Alfred Goldberg
  • Herman S Overkleeft
  • Sondra L Downey
  • Martijn Verdoes
  • Michael Screen
  • Alexandre A Pletnev
  • Matthew Britton
  • Tamer B Shabaneh
  • Anne C Mirabella
  • Owen M Wilkins
  • Alan Eastman
  • Ayrton L Goddard
  • Marcella M Lucas
  • Tina C Albershardt
  • Dmitri V Filippov
  • Wouter A van der Linden
  • Gijsbert A van der Marel
  • Hyoung Tae Kim
  • Paul F van Swieten
  • Regina Groisman
  • Chrystelle Brignone
  • Emily S Weyburne
  • David A Williams
  • Darcy J P Bates
  • Bethany L Salerni
  • Ryan S Soderquist
  • Paul P Geurink
  • Martijn D P Risseeuw
  • Mathias J Voges
  • Annet E M Blom
  • Omar Amir
  • Philip M Pelphrey
  • Dennis L Wright
  • Robert A Tokhunts
  • Ulrik Hillaert
  • Myra Sae-Heng
  • Lianne I Willems
  • Emlyn Samuel
  • Kwang Pyo Kim
  • Benedikt M Kessler
  • Rosa Orient Hern├índez
  • Adrianus M C H van den Nieuwendijk
  • K Matthew Scaglione
  • Michiel A Leeuwenburgh
  • Fernando Lledias
  • Steven P Gygi
  • Dorota Skowyra
  • Nogaye Gaye
  • Odile Chevallier
  • Yoshihiro Nakatani
  • Kiyoji Tanaka
  • Thierry Magnaldo
  • Isao Kuraoka
  • Annick Harel-Bellan
  • Steven R Grossman
  • Kathleen E Bradley

Detail Information

Publications18

  1. pmc Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib
    Tamer B Shabaneh
    Norris Cotton Cancer Center, The Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire, United States of America
    PLoS ONE 8:e56132. 2013
    ....
  2. doi request reprint A novel bullet hits the proteasome
    Alexei F Kisselev
    Department of Pharmacology and Toxicology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, 1 Medical Center Drive, Lebanon, NH 03756, USA Electronic address
    Cancer Cell 24:691-3. 2013
    ....
  3. pmc Proteasome inhibitors: an expanding army attacking a unique target
    Alexei F Kisselev
    Department of Pharmacology and Toxicology, Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, NH 03756, USA
    Chem Biol 19:99-115. 2012
    ..In addition, inhibitors of ATPases and deubiquitinases of 19S regulatory particles have been discovered in the last decade...
  4. doi request reprint Joining the army of proteasome inhibitors
    Alexei F Kisselev
    Norris Cotton Cancer Center and Department of Pharmacology and Toxicology, Dartmouth Medical School, Lebanon, NH 03756, USA
    Chem Biol 15:419-21. 2008
    ..2008) establish three natural products as novel proteasome inhibitors. These inhibitors, discovered in an unusual way, reveal a different mechanism of proteasome inhibition and suggest new therapeutic application of its inhibitors...
  5. pmc Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib
    Anne C Mirabella
    Department of Pharmacology and Toxicology, Dartmouth Medical School, Dartmouth College, Lebanon, NH 03756, USA
    Chem Biol 18:608-18. 2011
    ..Together with inhibitors of chymotrypsin- and caspase-like sites developed earlier, we provide the scientific community with a complete set of tools to separately modulate proteasome active sites in living cells...
  6. pmc Nature of pharmacophore influences active site specificity of proteasome inhibitors
    Michael Screen
    Department of Pharmacology and Toxicology, Dartmouth Medical School, Hanover, New Hampshire 03755, USA
    J Biol Chem 285:40125-34. 2010
    ..This increase in specificity is likely the basis of the decreased cytotoxicity of vinyl sulfone-based inhibitors to HeLa cells as compared with that of epoxyketone-based inhibitors...
  7. pmc Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites
    Matthew Britton
    Department of Pharmacology and Toxicology, Dartmouth Medical School, 1 Medical Center Drive, HB7936, Lebanon, NH 03756, USA
    Chem Biol 16:1278-89. 2009
    ..Thus, caspase-like and trypsin-like sites must be considered as cotargets of anticancer drugs...
  8. doi request reprint Cell-line-specific high background in the Proteasome-Glo assay of proteasome trypsin-like activity
    Owen M Wilkins
    Department of Pharmacology and Toxicology, Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA
    Anal Biochem 451:1-3. 2014
    ..Thus, Proteasome-Glo assay must be used with caution, and it is necessary to include a specific proteasome inhibitor to determine the background for each proteasome activity. ..
  9. pmc Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA
    Tina C Albershardt
    Department of Pharmacology and Toxicology, Dartmouth Medical School, Lebanon, New Hampshire 03756, USA
    J Biol Chem 286:24882-95. 2011
    ..Our findings highlight a novel signaling pathway through which many BH3 mimetics inhibit MCL1 and suggest the potential use of these agents as adjuvants in combination with various chemotherapy strategies...
  10. ncbi request reprint Monitoring activity and inhibition of 26S proteasomes with fluorogenic peptide substrates
    Alexei F Kisselev
    Department of Pharmacology and Toxicology, and Norris Cotton Cancer Center, Dartmouth Medical School, Lebanon, NH 03756, USA
    Methods Enzymol 398:364-78. 2005
    ..A novel assay of proteasome activity in crude cell extracts that allows rapid evaluation of the state of the proteasomes in cells treated with inhibitors is also described...
  11. pmc Azido-BODIPY acid reveals quantitative Staudinger-Bertozzi ligation in two-step activity-based proteasome profiling
    Martijn Verdoes
    Bio Organic Synthesis, Leiden Institute of Chemistry, P O Box 9502, 2300 RA Leiden, Netherlands
    Chembiochem 9:1735-8. 2008
  12. ncbi request reprint A cell-permeable inhibitor and activity-based probe for the caspase-like activity of the proteasome
    Paul F van Swieten
    Leiden Institute of Chemistry, Gorlaeus Laboratories, Leiden University, PO Box 9502, 2300 RA Leiden, Netherlands
    Bioorg Med Chem Lett 17:3402-5. 2007
    ..These compounds can be used as tools to study roles of beta1 and beta1i sites in generation of specific antigenic peptides and their potential role as co-targets of anti-cancer drugs...
  13. ncbi request reprint Certain pairs of ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s) synthesize nondegradable forked ubiquitin chains containing all possible isopeptide linkages
    Hyoung Tae Kim
    Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 282:17375-86. 2007
    ....
  14. pmc CSA-dependent degradation of CSB by the ubiquitin-proteasome pathway establishes a link between complementation factors of the Cockayne syndrome
    Regina Groisman
    Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Genes Dev 20:1429-34. 2006
    ..Moreover, we demonstrate the importance of CSB degradation for post-TCR recovery of transcription and for the Cockayne syndrome. Our results unravel for the first time the functional relationship between CSA and CSB...
  15. ncbi request reprint Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate
    Alexei F Kisselev
    Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 281:8582-90. 2006
    ....
  16. ncbi request reprint A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway
    Chrystelle Brignone
    Department of Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Oncogene 23:4121-9. 2004
    ..Moreover, our data suggest the possibility that ubiquitin ligase/UbL-UBA protein complexes, as exemplified by the MDM2/hHR23 complex, may serve a general role in regulating substrate degradation by the proteasome...
  17. ncbi request reprint The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites
    Alexei F Kisselev
    Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 278:35869-77. 2003
    ..Thus, occupancy of the caspase-like sites stimulates the trypsin-like activity of proteasomes, but substrates of the caspase-like sites inhibit the chymotrypsin-like activity by binding to a distinct noncatalytic site...
  18. ncbi request reprint Binding of hydrophobic peptides to several non-catalytic sites promotes peptide hydrolysis by all active sites of 20 S proteasomes. Evidence for peptide-induced channel opening in the alpha-rings
    Alexei F Kisselev
    Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 277:22260-70. 2002
    ..During protein breakdown, this peptide-induced channel opening may function to facilitate the release of products from the proteasome...